[1] Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig, 2013, 51(4):260-277.
[2] Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol, 2006, 33(1):98-105.
[3] Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol, 1998, 9(10):1053-1071.
[4] Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther, 2002, 1(3):227-235.
[5] Lim JH, Kim H, Choi WG, et al. Interstitial lung disease associated with FOLFOX chemotherapy. J Cancer Res Ther, 2010, 6(4):546-548.
[6] Vietor NO, George BJ. Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent. J Oncol Pharm Pract, 2012, 18(3):355-359.
[7] Ramanathan RK, Clark JW, Kemeny NE, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol, 2003, 21(15):2904-2911.
[8] Shimura T, Fuse N, Yoshino T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol, 2010, 21(10):2005-2010.
[9] De Weerdt A, Dendooven A, Snoeckx A, et al. Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient. BMC Cancer, 2017, 17(1):586.
[10] Karasu S, Sinci KA, Yildiz Y, et al. Chemotherapy-induced pulmonary toxicity mimicking COVID-19 pneumonia. Curr Med Imaging, 2021, 17(12):1510-1512.
[11] Mitsuboshi S, Kozakai H, Yamada H, et al. Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report. J Oncol Pharm Pract, 2018, 24(7):540-543.
[12] Pavlović M, Šeparović R, Silovski T, et al. Oxaliplatin induced pulmonary fibrosis: a case report. Acta Clin Croat, 2020, 59(4):761-764.
[13] El-Hout S, Lopez L, Schaeverbeke T, et al. Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports. Rheumatology (Oxford), 2021, 60(2):e47-e49.
[14] 张瑜, 王琳, 秦叔逵, 等. 奥沙利铂治疗相关间质性肺炎1例. 临床肿瘤学杂志, 2015, 20(09):859-861.
[15] 王光辉, 张金萍, 刘勇谋,等. 化疗药物致肺损伤1例. 临床肺科杂志, 2014, 19(12):2322-2323.
[16] 芦小燕, 戴幼琴, 邬亚妙, 等. 奥沙利铂致间质性肺炎. 药物不良反应杂志, 2020, 22(09):550-552.
[17] 陈佳音, 马洁, 童刚领, 等. 奥沙利铂相关性肺损伤的文献分析. 中国医院药学杂志, 2021, 41(10):1059-1063.
[18] Homma T, Kurokawa M, Yamamoto Y, et al. Oxaliplatin-induced lung injury with allergic reaction. Chin J Cancer Res, 2011, 23(3):232-235.
[19] Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol, 2004, 15(3):460-466.
[20] Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 2007, 33(1):9-23.
[21] Kinnula VL, Vuorinen K, Ilumets H, et al. Thiol proteins, redox modulation and parenchymal lung disease. Curr Med Chem, 2007, 14(2):213-222.
[22] Kalemci S, Tanrıverdi O, Şimşek A, et al. Evaluation of oxaliplatin-induced pulmonary toxicity in rats. Contemp Oncol (Pozn), 2019, 23(3):151-156.
[23] Usui K, Katou Y, Furushima K, et al. Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. Jpn J Clin Oncol, 2011, 41(4):498-502.
[24] Prochilo T, Abeni C, Bertocchi P, et al. Oxaliplatin-induced lung toxicity. Case report and review of the literature. Curr Drug Saf, 2012, 7(2):179-182.
[25] Garrido M, O'Brien A, González S, et al. Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report. Chest, 2007, 132(6):1997-1999.
[26] Moskovitz M, Wollner M, Haim N. Oxaliplatin-induced pulmonary toxicity in gastrointestinal malignancies: two case reports and review of the literature. Case Rep Oncol Med, 2015, 2015:341064.
[27] Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol, 2005, 29(3):321-326.
[28] Amemiya K, Semino-Mora C, Granger RP, et al. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol, 2000, 94(2):99-104.
[29] Fouqué A, Debure L, Legembre P. The CD95/CD95L signaling pathway: a role in carcinogenesis. Biochim Biophys Acta, 2014, 1846(1):130-141.
[30] Ge Y, Peng Q, Zhang S, et al. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol, 2015, 34(1):99-105.
[31] Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med, 2008, 102(2):273-279.
[32] Ohori H, Takahashi M, Ogasawara N, et al. Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Gan To Kagaku Ryoho, 2009, 36(2):295-298.
[33] Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol, 2006, 24(16):2549-2556. |
